ALEXIS Biochemicals: Orlistat

ALX-350-152

Revised 20-Jun-08

Orlistat
SYNONYMS	Tetrahydrolipstatin N-Formyl-L-leucine-(1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester
PRODUCT LINE	Obesity & Adipokines
PRODUCT CATEGORY	Fatty Acid Synthase [FAS] / Related Products

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-350-152-M050		50 mg	40.00 USD
ALX-350-152-M250		250 mg	120.00 USD

Product Specification

FORMULA:	C₂₉H₅₃NO₅
MW:	495.7
CAS NUMBER:	96829-58-2
MERCK INDEX:	14: 6869
SOURCE/HOST:	Synthetic. Originally isolated from Streptomyces sp.
PURITY:	≥97%
APPEARANCE:	White to off-white solid.
SOLUBILITY:	Soluble in DMSO or 100% ethanol.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C
USE/STABILITY:	Stock solutions are stable for up to 6 weeks when stored at -20°C.
HANDLING:	After reconstitution, prepare aliquots and store at -20°C. Protect from light and moisture.

Product Description

Cell permeable, irreversible inhibitor of gastric and pancreatic lipases. Shows only minimal activity against amylase, trypsin, chymotrypsin, or phospholipase A₂(PLA₂). Partially inhibits the hydrolysis of triglycerides and lowers the absorption of dietary fat and promotes weight loss. Anti-obesity drug. Exhibits antitumor activity by inhibition of the thioesterase domain of fatty acid synthase (FAS) both in vitro and in vivo.

Product Specific Literature References

Interactions of lipoprotein lipase with the active-site inhibitor tetrahydrolipstatin (Orlistat): A. Lookene, et al.; Eur. J. Biochem. 222, 395 (1994) Abstract
Degree of in vivo inhibition of human gastric and pancreatic lipases by Orlistat (Tetrahydrolipstatin, THL) in the stomach and small intestine: B. Sternby, et al.; Clin. Nutr. 21, 395 (2002) Abstract
A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2: L.M. Knowles, et al.; J. Biol. Chem. 279, 30540 (2004) Abstract; Full Text
Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity: S.J. Kridel, et al.; Cancer Res. 64, 2070 (2004) Abstract
Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene: J.A. Menendez, et al.; Ann. Oncol. 16, 1253 (2005) Abstract
Differential uptake of subfractions of triglyceride-rich lipoproteins by THP-1 macrophages: A.M. Palmer, et al.; Atherosclerosis 180, 233 (2005) Abstract
Orlistat and sibutramine beyond weight loss: E. Mannucci, et al.; Nutr. Metab. Cardiovasc. Dis. 70, 1228 (2008) Abstract

Further Categories Containing This Product:

Natural Products - Antitumor Reagents • Obesity & Diabetes Other Products

header picture © micronaut.ch, another CS2 website

Online Product Ordering

Clipboard [0]

Your items will be kept only for the duration of your visit.